Logo image of BIAF

BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Fundamental Analysis

NASDAQ:BIAF - Nasdaq - US09076W1099 - Common Stock - Currency: USD

0.47  +0.02 (+4.68%)

After market: 0.445 -0.02 (-5.32%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BIAF. BIAF was compared to 566 industry peers in the Biotechnology industry. Both the profitability and financial health of BIAF have multiple concerns. BIAF does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BIAF had negative earnings in the past year.
BIAF had a negative operating cash flow in the past year.
BIAF had negative earnings in each of the past 5 years.
BIAF had a negative operating cash flow in each of the past 5 years.
BIAF Yearly Net Income VS EBIT VS OCF VS FCFBIAF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

BIAF's Return On Assets of -138.78% is on the low side compared to the rest of the industry. BIAF is outperformed by 83.39% of its industry peers.
Looking at the Return On Equity, with a value of -347.42%, BIAF is doing worse than 75.44% of the companies in the same industry.
Industry RankSector Rank
ROA -138.78%
ROE -347.42%
ROIC N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIAF Yearly ROA, ROE, ROICBIAF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

Looking at the Gross Margin, with a value of 36.09%, BIAF is in the better half of the industry, outperforming 74.03% of the companies in the same industry.
BIAF does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 36.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIAF Yearly Profit, Operating, Gross MarginsBIAF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

0

2. Health

2.1 Basic Checks

BIAF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BIAF has been increased compared to 1 year ago.
Compared to 1 year ago, BIAF has a worse debt to assets ratio.
BIAF Yearly Shares OutstandingBIAF Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
BIAF Yearly Total Debt VS Total AssetsBIAF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

BIAF has an Altman-Z score of -13.45. This is a bad value and indicates that BIAF is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -13.45, BIAF is not doing good in the industry: 79.15% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.18 indicates that BIAF is not too dependend on debt financing.
BIAF has a Debt to Equity ratio of 0.18. This is in the lower half of the industry: BIAF underperforms 69.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -13.45
ROIC/WACCN/A
WACC9.43%
BIAF Yearly LT Debt VS Equity VS FCFBIAF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 0.87 indicates that BIAF may have some problems paying its short term obligations.
The Current ratio of BIAF (0.87) is worse than 90.11% of its industry peers.
BIAF has a Quick Ratio of 0.87. This is a bad value and indicates that BIAF is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.86, BIAF is not doing good in the industry: 89.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.86
BIAF Yearly Current Assets VS Current LiabilitesBIAF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.65% over the past year.
BIAF shows a strong growth in Revenue. In the last year, the Revenue has grown by 269.55%.
EPS 1Y (TTM)16.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.09%
Revenue 1Y (TTM)269.55%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-0.24%

3.2 Future

BIAF is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.06% yearly.
BIAF is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -12.94% yearly.
EPS Next Y45.12%
EPS Next 2Y32.06%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-36.83%
Revenue Next 2Y-12.94%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

BIAF Yearly Revenue VS EstimatesBIAF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2M 4M 6M 8M
BIAF Yearly EPS VS EstimatesBIAF Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BIAF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BIAF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIAF Price Earnings VS Forward Price EarningsBIAF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIAF Per share dataBIAF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as BIAF's earnings are expected to grow with 32.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.06%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BIAF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOAFFINITY TECHNOLOGIES INC

NASDAQ:BIAF (4/30/2025, 8:00:01 PM)

After market: 0.445 -0.02 (-5.32%)

0.47

+0.02 (+4.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31 2025-03-31/bmo
Earnings (Next)05-20 2025-05-20
Inst Owners3.37%
Inst Owner Change0%
Ins Owners15.17%
Ins Owner Change6.68%
Market Cap8.58M
Analysts82.86
Price Target6.12 (1202.13%)
Short Float %2.76%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.82%
Min EPS beat(2)-47.06%
Max EPS beat(2)-4.58%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.86%
Min Revenue beat(2)-10.46%
Max Revenue beat(2)-9.27%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)5.88%
EPS NQ rev (3m)5.88%
EPS NY rev (1m)31.82%
EPS NY rev (3m)31.82%
Revenue NQ rev (1m)-19.47%
Revenue NQ rev (3m)-19.47%
Revenue NY rev (1m)-47.38%
Revenue NY rev (3m)-47.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.92
P/FCF N/A
P/OCF N/A
P/B 3.3
P/tB 20.31
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0.51
BVpS0.14
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -138.78%
ROE -347.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 36.09%
FCFM N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.44
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.06%
Cap/Sales 0.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.86
Altman-Z -13.45
F-Score4
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)740.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.09%
EPS Next Y45.12%
EPS Next 2Y32.06%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)269.55%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-0.24%
Revenue Next Year-36.83%
Revenue Next 2Y-12.94%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.32%
OCF growth 3YN/A
OCF growth 5YN/A